Novartis AG ADR (NYSE:NVS) — Market Cap & Net Worth
Market Cap & Net Worth: Novartis AG ADR (NVS)
Novartis AG ADR (NYSE:NVS) has a market capitalization of $281.41 Billion ($281.41 Billion) as of April 27, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #59 globally and #40 in its home market, demonstrating a -3.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novartis AG ADR's stock price $147.48 by its total outstanding shares 1908151679 (1.91 Billion).
Novartis AG ADR Market Cap History: 2015 to 2026
Novartis AG ADR's market capitalization history from 2015 to 2026. Data shows growth from $96.09 Billion to $277.58 Billion (9.81% CAGR).
Index Memberships
Novartis AG ADR is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.12 Trillion | 9.03% | #5 of 24 |
Weight: Novartis AG ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novartis AG ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novartis AG ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.80x
Novartis AG ADR's market cap is 4.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.72x
Novartis AG ADR's market cap is 18.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $84.75 Billion | $49.44 Billion | $6.71 Billion | 1.71x | 12.63x |
| 2017 | $101.51 Billion | $43.40 Billion | $7.70 Billion | 2.34x | 13.18x |
| 2018 | $107.83 Billion | $46.10 Billion | $12.61 Billion | 2.34x | 8.55x |
| 2019 | $139.25 Billion | $48.68 Billion | $11.73 Billion | 2.86x | 11.87x |
| 2020 | $144.21 Billion | $49.90 Billion | $8.07 Billion | 2.89x | 17.86x |
| 2021 | $139.25 Billion | $43.97 Billion | $24.02 Billion | 3.17x | 5.80x |
| 2022 | $150.83 Billion | $43.46 Billion | $6.96 Billion | 3.47x | 21.69x |
| 2023 | $185.58 Billion | $46.66 Billion | $14.85 Billion | 3.98x | 12.50x |
| 2024 | $185.68 Billion | $51.72 Billion | $11.94 Billion | 3.59x | 15.55x |
| 2025 | $263.08 Billion | $54.81 Billion | $14.06 Billion | 4.80x | 18.72x |
Competitor Companies of NVS by Market Capitalization
Companies near Novartis AG ADR in the global market cap rankings as of April 27, 2026.
Key companies related to Novartis AG ADR by market ranking:
- Eli Lilly and Company (SA:LILY34): Ranked #16 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Eli Lilly and Company (NYSE:LLY): Ranked #18 globally with a market cap of $791.16 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #22 globally with a market cap of $548.11 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #39 globally with a market cap of $351.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #18 | Eli Lilly and Company | NYSE:LLY | $791.16 Billion | $883.96 |
| #22 | Johnson & Johnson | NYSE:JNJ | $548.11 Billion | $227.50 |
| #39 | AbbVie Inc | NYSE:ABBV | $351.35 Billion | $198.71 |
Novartis AG ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Novartis AG ADR's market cap moved from $96.09 Billion to $ 277.58 Billion, with a yearly change of 9.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $277.58 Billion | +5.51% |
| 2025 | $263.08 Billion | +41.68% |
| 2024 | $185.68 Billion | +0.06% |
| 2023 | $185.58 Billion | +23.03% |
| 2022 | $150.83 Billion | +8.32% |
| 2021 | $139.25 Billion | -3.43% |
| 2020 | $144.21 Billion | +3.56% |
| 2019 | $139.25 Billion | +29.14% |
| 2018 | $107.83 Billion | +6.22% |
| 2017 | $101.51 Billion | +19.77% |
| 2016 | $84.75 Billion | -11.80% |
| 2015 | $96.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Novartis AG ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $281.41 Billion USD |
| MoneyControl | $281.41 Billion USD |
| MarketWatch | $281.41 Billion USD |
| marketcap.company | $281.41 Billion USD |
| Reuters | $281.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more